Gene therapy for prostate cancer

Yehoshua Gdor; Terry L. Timme; Brian J. Miles; Dov Kadmon; Timothy C. Thompson

doi:10.1586/14737140.2.3.309

Gene therapy for prostate cancer

Yehoshua Gdor, Terry L. Timme, Brian J. Miles, Dov Kadmon, Timothy C. Thompson

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Prostate cancer is the most common noncutaneous cancer in man. When confined to the prostate it can be cured by radical prostatectomy or irradiation therapy. However, there are no curative therapies for locally advanced, recurrent or metastatic disease. Prostate cancer gene therapy has recently transitioned from preclinical studies to clinical trials with the goal of developing novel treatments for prostate cancer. The greatest challenge in treating advanced prostate cancer is therapeutic access to and the elimination of metastases. This review details two aspects of prostate cancer gene therapy, the types of delivery systems under development and specific categories of therapeutic genes available with an emphasis on the mechanism of action of specific gene therapy strategies.

Original language	English (US)
Pages (from-to)	309-321
Number of pages	13
Journal	Expert review of anticancer therapy
Volume	2
Issue number	3
DOIs	https://doi.org/10.1586/14737140.2.3.309
State	Published - 2002
Externally published	Yes

Keywords

Adenovirus
Gene therapy
HSV-tk
IL-12
Immunotherapy
Metastasis
Prostate cancer

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1586/14737140.2.3.309

Cite this

@article{8d471601cba34addb7284cdd50a8c735,

title = "Gene therapy for prostate cancer",

abstract = "Prostate cancer is the most common noncutaneous cancer in man. When confined to the prostate it can be cured by radical prostatectomy or irradiation therapy. However, there are no curative therapies for locally advanced, recurrent or metastatic disease. Prostate cancer gene therapy has recently transitioned from preclinical studies to clinical trials with the goal of developing novel treatments for prostate cancer. The greatest challenge in treating advanced prostate cancer is therapeutic access to and the elimination of metastases. This review details two aspects of prostate cancer gene therapy, the types of delivery systems under development and specific categories of therapeutic genes available with an emphasis on the mechanism of action of specific gene therapy strategies.",

keywords = "Adenovirus, Gene therapy, HSV-tk, IL-12, Immunotherapy, Metastasis, Prostate cancer",

author = "Yehoshua Gdor and Timme, {Terry L.} and Miles, {Brian J.} and Dov Kadmon and Thompson, {Timothy C.}",

year = "2002",

doi = "10.1586/14737140.2.3.309",

language = "English (US)",

volume = "2",

pages = "309--321",

journal = "Expert review of anticancer therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "3",

}

TY - JOUR

T1 - Gene therapy for prostate cancer

AU - Gdor, Yehoshua

AU - Timme, Terry L.

AU - Miles, Brian J.

AU - Kadmon, Dov

AU - Thompson, Timothy C.

PY - 2002

Y1 - 2002

N2 - Prostate cancer is the most common noncutaneous cancer in man. When confined to the prostate it can be cured by radical prostatectomy or irradiation therapy. However, there are no curative therapies for locally advanced, recurrent or metastatic disease. Prostate cancer gene therapy has recently transitioned from preclinical studies to clinical trials with the goal of developing novel treatments for prostate cancer. The greatest challenge in treating advanced prostate cancer is therapeutic access to and the elimination of metastases. This review details two aspects of prostate cancer gene therapy, the types of delivery systems under development and specific categories of therapeutic genes available with an emphasis on the mechanism of action of specific gene therapy strategies.

AB - Prostate cancer is the most common noncutaneous cancer in man. When confined to the prostate it can be cured by radical prostatectomy or irradiation therapy. However, there are no curative therapies for locally advanced, recurrent or metastatic disease. Prostate cancer gene therapy has recently transitioned from preclinical studies to clinical trials with the goal of developing novel treatments for prostate cancer. The greatest challenge in treating advanced prostate cancer is therapeutic access to and the elimination of metastases. This review details two aspects of prostate cancer gene therapy, the types of delivery systems under development and specific categories of therapeutic genes available with an emphasis on the mechanism of action of specific gene therapy strategies.

KW - Adenovirus

KW - Gene therapy

KW - HSV-tk

KW - IL-12

KW - Immunotherapy

KW - Metastasis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0036081075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036081075&partnerID=8YFLogxK

U2 - 10.1586/14737140.2.3.309

DO - 10.1586/14737140.2.3.309

M3 - Review article

C2 - 12113054

AN - SCOPUS:0036081075

SN - 1473-7140

VL - 2

SP - 309

EP - 321

JO - Expert review of anticancer therapy

JF - Expert review of anticancer therapy

IS - 3

ER -

Gene therapy for prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this